Search

Your search keyword '"Malogolowkin, Marcio H"' showing total 97 results
Start Over Author "Malogolowkin, Marcio H"
97 results on '"Malogolowkin, Marcio H"'

53. Fibrolamellar hepatocellular carcinoma in children and adolescents

Author

Katzenstein, Howard M., Krailo, Mark D., Malogolowkin, Marcio H., Ortega, Jorge A., Wenchun Qu, Douglass, Edwin C., Feusner, James H., Reynolds, Marleta, Quinn, John J., Newman, Kurt, Finegold, Milton J., Haas, Joel E., Sensel, Martha G., Castleberry, Robert P., and Bowman, Laura C.

Subjects
Liver cancer -- Demographic aspects, Liver cancer -- Physiological aspects, Liver cancer -- Prognosis, Liver cancer -- Patient outcomes, Cancer in children -- Demographic aspects, Cancer in children -- Physiological aspects, Cancer in children -- Prognosis, Cancer in children -- Patient outcomes, Cancer patients -- Prognosis, Health
Published
2003

55. Alfa-feto protein (AFP) as a predictor of outcome for children with germ cell tumors: A report from the malignant germ cell international consortium.

Author

O'Neill, Allison Frances, primary, Xia, Caihong, additional, Krailo, Mark D., additional, Shaikh, Furqan, additional, Pashankar, Farzana D., additional, Billmire, Deborah F, additional, Olson, Thomas Arthur, additional, Amatruda, James F., additional, Villaluna, Doojduen, additional, Malogolowkin, Marcio H., additional, Rodriguez-Galindo, Carlos, additional, and Frazier, A. Lindsay, additional

Published
2019
Full Text
View/download PDF

57. Reply to D.M. Green

Author

Dix, David B., primary, Seibel, Nita L., additional, Chi, Yueh-Yun, additional, Khanna, Geetika, additional, Mullen, Elizabeth A., additional, Geller, James I., additional, Kalapurakal, John A., additional, Ehrlich, Peter F., additional, Malogolowkin, Marcio H., additional, Fernandez, Conrad V., additional, and Dome, Jeffrey S., additional

Published
2018
Full Text
View/download PDF

61. Gonadal dysgenesis is associated with worse outcomes in patients with ovarian nondysgerminomatous tumors: A report of the Children's Oncology Group AGCT 0132 study

Author

Dicken, Bryan J., primary, Billmire, Deborah F., additional, Krailo, Mark, additional, Xia, Caihong, additional, Shaikh, Furqan, additional, Cullen, John W., additional, Olson, Thomas A., additional, Pashankar, Farzana, additional, Malogolowkin, Marcio H., additional, Amatruda, James F., additional, Rescorla, Frederick J., additional, Egler, Rachel A., additional, Ross, Jonathan H., additional, Rodriguez-Galindo, Carlos, additional, and Frazier, A. Lindsay, additional

Published
2017
Full Text
View/download PDF

65. Neonatal Medical Exposures and Characteristics of Low Birth Weight Hepatoblastoma Cases: A Report From the Children's Oncology Group

Author

Turcotte, Lucie M., Georgieff, Michael K., Ross, Julie A., Feusner, James H., Tomlinson, Gail E., Malogolowkin, Marcio H., Krailo, Mark D., Nicole Miller, Rachel Fonstad, and Logan Spector

Subjects
NICU, Hepatoblastoma, Parenteral Nutrition, Pediatric Research Initiative, Pediatric Cancer, case-control study, Clinical Sciences, Oncology and Carcinogenesis, Gestational Age, Reproductive health and childbirth, Low Birth Weight and Health of the Newborn, Article, Paediatrics and Reproductive Medicine, Clinical Research, Preterm, Infant Mortality, 2.1 Biological and endogenous factors, 2.2 Factors relating to the physical environment, Humans, low birth weight, Oncology & Carcinogenesis, Aetiology, Cancer, Pediatric, Prevention, Liver Neoplasms, Infant, Newborn, Infant, Perinatal Period - Conditions Originating in Perinatal Period, Infant, Low Birth Weight, Newborn, exposure, Case-Control Studies, Total, Parenteral Nutrition, Total, 2.4 Surveillance and distribution
Abstract

BackgroundHepatoblastoma is a malignancy of young children. Low birth weight is associated with significantly increased risk of hepatoblastoma and neonatal medical exposures are hypothesized as contributors. This study represents the largest case-control study of hepatoblastoma to date and aimed to define the role of neonatal exposures in hepatoblastoma risk among low birth weight children.ProcedureIncident hepatoblastoma cases who were born

Published
2014

66. Reduced and compressed cisplatin-based chemotherapy in children and adolescents with intermediate-risk extracranial malignant germ cell tumors: A report from the Children’s Oncology Group.

Author

Shaikh, Furqan, primary, Cullen, John W, additional, Olson, Thomas Arthur, additional, Pashankar, Farzana, additional, Malogolowkin, Marcio H., additional, Amatruda, James, additional, Villaluna, Doojduen, additional, Krailo, Mark D., additional, Billmire, Deborah F, additional, Rescorla, Frederick J, additional, Egler, Rachel A., additional, Dicken, Bryan J, additional, Ross, Jonathan H, additional, Schlatter, Marc, additional, Rodriguez-Galindo, Carlos, additional, and Frazier, A. Lindsay, additional

Published
2016
Full Text
View/download PDF

67. Outcome of patients with stage II/favorable histology Wilms tumor with and without local tumor spill. A report from the National Wilms Tumor Study Group

Author

Green, Daniel M, Breslow, Norman E, D'Angio, Giulio J, Malogolowkin, Marcio H, Ritchey, Michael L, Evans, Audrey E, Beckwith, J Bruce, Perlman, Elizabeth J, Shamberger, Robert C, Peterson, Susan, Grundy, Paul E, Dome, Jeffrey S, Thomas, Patrick RM, and Kalapurakal, John A

Subjects
Clinical Sciences, Oncology and Carcinogenesis, Kaplan-Meier Estimate, doxorubicin, radiation therapy, vincristine, Nephrectomy, Wilms Tumor, Article, Disease-Free Survival, Paediatrics and Reproductive Medicine, Rare Diseases, Neoplasm Seeding, Antineoplastic Combined Chemotherapy Protocols, Humans, Oncology & Carcinogenesis, Cancer, Neoplasm Staging, Radiotherapy, Combined Modality Therapy, Kidney Neoplasms, Treatment Outcome, Vincristine, oncology, Dactinomycin, actinomycin D
Abstract

BackgroundIntra-operative tumor spill increases the risk of local recurrence of Wilms tumor, and adversely impacts relapse-free (RFS) and overall survival (OS) rates.MethodsSurgical checklists, operative notes, institutional pathology reports, central pathology review and flow sheets of 602 patients registered between August 1986 and September 1994 on National Wilms Tumor Study-4 as randomized, followed or switched and coded as Final Stage II, favorable histology (FH) were reviewed. RFS and OS were estimated using the Kaplan-Meier method. Hazard ratios (HRs) were estimated using the Cox model and tested for statistical significance by the log-rank test.ResultsFour hundred ninety-nine patients were found after review to have Stage II, FH Wilms tumor. The 8-year RFS percentages were 85.0% (95% confidence interval (CI): 81.1%, 88.1%) for those with no spill compared to 75.7% (65.8%, 83.2%) for those with spill. The 8-year OS percentages were 95.6% (93.1%, 97.3%) for those with no spill compared to 90.3% (82.2%, 94.9%) for those with spill. The HR for relapse among those with spill was 1.55 ((95%CI: 0.97,2.51), P = 0.067) and the HR for death was 1.94 ((0.92,4.09), P = 0.077).ConclusionsRFS and OS were lower for patients who had intra-operative tumor spill. The majority of NWTS Stage II, FH patients with intra-operative tumor spill have an overall excellent outcome when treated with two drug chemotherapy (vincristine and actinomycin D) and no abdominal irradiation.

Published
2013

68. Omission of lung radiation in patients with stage IV favorable histology Wilms Tumor (FHWT) showing complete lung nodule response after chemotherapy: A report from Children’s Oncology Group study AREN0533.

Author

Dix, David B., primary, Gratias, Eric J., additional, Seibel, Nita, additional, Anderson, James Robert, additional, Mullen, Elizabeth Anne, additional, Geller, James I., additional, Khanna, Geetika, additional, Kalapurakal, John A., additional, Perlman, Elizabeth Jones, additional, Ehrlich, Peter F., additional, Malogolowkin, Marcio H., additional, Grundy, Paul Edward, additional, and Dome, Jeffrey S., additional

Published
2015
Full Text
View/download PDF

69. Augmentation of therapy for favorable-histology Wilms Tumor with combined loss of heterozygosity of chromosomes 1p and 16q: A report from the Children’s Oncology Group studies AREN0532 and AREN0533.

Author

Dix, David B., primary, Fernandez, Conrad Vincent, additional, Chi, Yueh-Yun, additional, Anderson, James Robert, additional, Mullen, Elizabeth Anne, additional, Geller, James I., additional, Gratias, Eric J., additional, Khanna, Geetika, additional, Kalapurakal, John A., additional, Perlman, Elizabeth Jones, additional, Seibel, Nita, additional, Ehrlich, Peter F., additional, Malogolowkin, Marcio H., additional, Gow, Kenneth William, additional, Hamilton, Thomas Edward, additional, Grundy, Paul Edward, additional, and Dome, Jeffrey, additional

Published
2015
Full Text
View/download PDF

70. Liver Tumors

Author

Malogolowkin, Marcio H., primary, Zimmermann, Arthur, additional, and Plaschkes, Jack, additional

Full Text
View/download PDF

71. Treatment of stage IV favorable histology Wilms tumor with incomplete lung metastasis response after chemotherapy: A report from Children’s Oncology Group study AREN0533.

Author

Dix, David B., primary, Gratias, Eric J., additional, Seibel, Nita, additional, Anderson, James Robert, additional, Mullen, Elizabeth Anne, additional, Geller, James I., additional, Khanna, Geetika, additional, Kalapurakal, John A., additional, Perlman, Elizabeth Jones, additional, Ehrlich, Peter F., additional, Malogolowkin, Marcio H., additional, Grundy, Paul Edward, additional, and Dome, Jeffrey, additional

Published
2014
Full Text
View/download PDF

72. Hepatoblastoma state of the art

Author

Czauderna, Piotr, primary, Lopez-Terrada, Dolores, additional, Hiyama, Eiso, additional, Häberle, Beate, additional, Malogolowkin, Marcio H., additional, and Meyers, Rebecka L., additional

Published
2014
Full Text
View/download PDF

74. Outcome of patients with stage II/favorable histology wilms tumor with and without local tumor spill: A report from the National Wilms Tumor Study Group

Author

Green, Daniel M., primary, Breslow, Norman E., additional, D'Angio, Giulio J., additional, Malogolowkin, Marcio H., additional, Ritchey, Michael L., additional, Evans, Audrey E., additional, Beckwith, J. Bruce, additional, Perlman, Elizabeth J., additional, Shamberger, Robert C., additional, Peterson, Susan, additional, Grundy, Paul E., additional, Dome, Jeffrey S., additional, Thomas, Patrick R.M., additional, and Kalapurakal, John A., additional

Published
2013
Full Text
View/download PDF

75. Outcome in congenital hepatoblastoma compared with previously reported data.

Author

Trobaugh-Lotrario, Angela D, primary, Chaiyachati, Barbara H, additional, Meyers, Rebecka, additional, Haberle, Beate, additional, Tomlinson, Gail Elizabeth, additional, Katzenstein, Howard M., additional, Malogolowkin, Marcio H., additional, von Schweinitz, Dietrich, additional, Krailo, Mark D., additional, and Feusner, James Henry, additional

Published
2013
Full Text
View/download PDF

77. Pleuropulmonary Blastoma

Author

Venkatramani, Rajkumar, primary, Malogolowkin, Marcio H., additional, Wang, Larry, additional, and Mascarenhas, Leo, additional

Published
2012
Full Text
View/download PDF

87. Liver Tumors.

Author

Bleyer, W. Archie, Barr, Ronald D., Malogolowkin, Marcio H., Zimmermann, Arthur, and Plaschkes, Jack

Published
2007
Full Text
View/download PDF

91. Mycotic Aneurysm of the Thoracic Aorta Due to Aspergillus terreus: Case Report and Review.

Author

Silva, Monica E., Malogolowkin, Marcio H., Hall, Theodore R., Sadeghi, Ali M., and Krogstad, Paul

Subjects
*AORTIC aneurysms, *ASPERGILLUS
Abstract

Presents a study on mycotic aneurysms of the aorta caused by Aspergillus terreus. Details of the case of a boy with acute myelogenous leukemia in remission; Information on mycotic aneurysm; Clinical data for reported patients with mycotic aneurysms due to Aspergillus species.

Published
2000
Full Text
View/download PDF

92. Immature Teratomas: Identification of Patients at Risk for Malignant Recurrence.

Author

Malogolowkin, Marcio H., Ortega, Jorge A., Krailo, Mark, Gonzalez, Orlando, Mahour, G. Hossein, Landing, Benjamin H., and Siegel, Stuart E.

Abstract

We investigated the significance of immature elements in an otherwise benign teratoma in 28 patients with immature teratomas diagnosed and treated at the Childrens Hospital of Los Angeles from 1941 to 1986. Different characteristics, including age, sex, primary tumor site, type of surgery (complete resection vs. partial resection or biopsy), and preoperative levels of alpha-fetoprotein (AFP) were analyzed to evaluate their association with risk of subsequent local malignant recurrence. After a median follow-up of 6 years, 21 patients are alive with no recurrence of the tumor (72% event-free survival). One patient died from infection after surgery and six patients had local malignant tumor recurrence within 1 year from diagnosis. Of the 28 patients, 12 had AFP levels measured at diagnosis. Eight patients had normal levels with no further evidence of tumor recurrence, and four had elevated levels with three tumor recurrences. Our experience demonstrates that only at the time of diagnosis do AFP levels correlate with a subsequent malignant behavior of these tumors ( = .004). Those patients with immature teratomas and elevated AFP levels at diagnosis should receive adjuvant chemotherapy after the initial surgical resection [J Natl Cancer Inst 81:870–874, 1989] [ABSTRACT FROM PUBLISHER]

Published
1989

95. Upfront or delayed surgery in resectable hepatoblastoma: analysis from the children's hepatic tumors international collaboration database.

Author

Hiyama E, Hishiki T, Yoshimura K, Krailo M, Maibach R, Haeberle B, Rangaswami A, Lopez-Terrada D, Malogolowkin MH, Ansari M, Alaggio R, O'Neill AF, Trobaugh-Lotrario AD, Watanabe K, Schmid I, Ranganathan S, Tanaka Y, Inoue T, Piao J, Lin J, Czauderna P, Meyers RL, and Aronson DC

Abstract

Background: In the treatment of resectable hepatoblastoma (HB), it has not been established whether upfront surgery (UF) at diagnosis or neoadjuvant chemotherapy and delayed surgery (DL) is preferred. We compared patients with localized HB who underwent either UF, or DL after neoadjuvant chemotherapy in the Children's Hepatic tumors International Collaboration (CHIC) database of 1605 cases enrolled in eight multicenter hepatoblastoma trials between 1988 and 2010., Methods: Among the 512 resectable HB patients who had PRETEXT (PRETreament EXTent of disease) I or II unruptured tumors at diagnosis without extrahepatic invasion, distant metastases, or massive vascular invasion, 172 underwent UF and 340 underwent DL. The primary outcomes were event-free and overall survivals after start of treatment in these two groups. Survival analysis was performed using the Kaplan-Maier analysis with long-rank tests and multivariable Cox regression models., Findings: Complete resection rates were comparable (93.6% in UF and 89.7% in DL). The total cycles of chemotherapy of DL (median:6) were significantly more than those of UF (median:4) ( P  < 0.01). The 5-year event-free survival (EFS) was 90.6% and 86.6% ( P  = 0.89) in the UF and DL cohorts, respectively. The surgical complications, recurrence rates, and late complications were not significantly different between the cohorts but the EFS rates of DL patients with a low alpha-fetoprotein (AFP) level (100-999 ng/mL) or older age at diagnosis (≥3 years old) were significantly worse than others., Interpretation: The outcomes, surgical resectability, and complications were not significantly different between the UF and DL groups. Eligible patients with a low AFP level (<1000 ng/mL) or older age (≥3 years old) showed better outcomes in the UF group and might be considered for initial resection., Funding: European Network for Cancer Research in Children and Adolescents, funded through the Framework Program 7 of the European Commission; Children's Oncology Group Cure Search grant contributed by the Hepatoblastoma Foundation; Practical Research for Innovative Cancer Control and Project Promoting Clinical Trials for Development of New Drugs and Medical Devices, Japan Agency for Medical Research and Development; Japan Society for the Promotion of Science; and Swiss Cancer Research grant., Competing Interests: We declare no competing interests., (© 2024 The Authors.)

Published
2024
Full Text
View/download PDF

97. Pleuropulmonary blastoma: a single-institution experience.

Author

Venkatramani R, Malogolowkin MH, Wang L, and Mascarenhas L

Subjects
Child, Preschool, Female, Humans, Infant, Infant, Newborn, Lung Neoplasms mortality, Lung Neoplasms pathology, Lung Neoplasms therapy, Male, Pulmonary Blastoma mortality, Pulmonary Blastoma pathology, Pulmonary Blastoma therapy
Abstract

Pleuropulmonary blastoma (PPB) is a rare primary intrathoracic mesenchymal malignancy that occurs exclusively in early childhood. Twelve patients were diagnosed with PPB (1 type I, 5 type II, and 6 type III) between 1979 and 2009 at our institution. Upfront complete tumor resection was successful in 5 of 6 patients. Six patients had biopsy followed by neoadjuvant chemotherapy, 2 had complete tumor resection, and 2 had microscopic residual disease after surgery. All patients received vincristine, dactinomycin, and cyclophosphamide chemotherapy. Eight received additional chemotherapy with doxorubicin, cisplatin, etoposide, or ifosfamide. Three patients received local irradiation. The 5-year event-free and overall survivals were 33% ± 14% and 42% ± 14%, respectively. Median time to progression was 8 months. Five of 9 patients with gross total resection survived, whereas all 3 with gross residual disease died. Three of 5 survivors did not receive radiation. A high index of suspicion for PPB must be maintained in all patients diagnosed with intrathoracic sarcoma in early childhood. Gross total resection is necessary for cure, and selected patients do not require radiation therapy.

Published
2012
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results